Novel clinical research conducted by the Lambert Initiative’s clinical team and collaborators within Australia
Cannabidiol (CBD) is a non-intoxicating constituent of the Cannabis sativa plant that is now widely used as both a prescription drug and a nutraceutical product. CBD exhibits a good overall safety and tolerability profile and has a low potential for abuse.
There has been recent evidence supporting the use of CBD to treat anxiety disorders and is generally demonstrated at relatively high oral doses of CBD. However, in North America and many European countries, a wide range of ‘low-dose’ CBD products are widely available in pharmacies and health food stores as “wellness” products
This study aims to determine the effects of 'low dose' cannabis-based medication on stress and nausea in healthy participants using Virtual Reality scenarios that are designed to elicit mild stress and nausea responses.
You may be eligible if you are:
Trial Coordinator: Zeeta Bawa (University of Sydney)
Chief Investigator: Professor Iain McGregor (University of Sydney).
You can register your interest via our online pre-screening survey.
Human Research Ethics Committee approval has been granted by The University of Sydney [2023/307].
CBD has demonstrated promising reductions in treatment-resistant anxiety in young persons. CBD may reduce the anxiety provoking re-feeding phases of MFBT improving response to MFBT.
The ‘CAFTAN’ study is an open-label pilot. 800mg/day CBD will be administered every day for 3 months alongside MFBT. Participants will also have an option to enrol into an extension arm of the trial and continue taking CBD for an additional 3 months if deemed appropriate by research team and patients care team.
You may qualify if you:
This is a collaboration between the Lambert Initiative for Cannabinoid Therapeutics and the InsideOut Institute for Eating Disorders.
Trial Coordinator: Sarah-Catherine Rodan (University of Sydney)
For more information and to register your interest, visit the CAFTAN website.
If you have any questions, please contact the Trial Coordinator (firstname.lastname@example.org)
Human Research Ethics Committee approval has been granted by the Sydney Local Health District [X21-0440].
Findings from a recent pilot study conducted by the Lambert Initiative suggest that CBD may increase feelings of pleasure during exercise and alter physiological processes (e.g., oxygen consumption) in such a way that improves exercise tolerance.
While these results suggest that CBD may have potential as an exercise aid for patient populations, further investigation is required to better understand its effects.
This randomised, double- blind, placebo-controlled, crossover trial will investigate the effect of CBD on exercise tolerance in twenty-five healthy individuals. Endurance-trained male and female runners will be recruited for this initial investigation.
Participants will complete three research sessions involving a controlled bout of running exercise on a treadmill (60 min), a short (30 min) recovery, and an incremental run to volitional exhaustion.
This is a collaboration between The Lambert Initiative for Cannabinoid Therapuetics and Griffith University.
Chief Investigator: Professor Paul Haber (Royal Prince Alfred Hospital)
Project Coordinator: Ayshe Sahinovic (The University of Sydney)
If you are interested in participating in this study, please contact Ayshe Sahinovic (email@example.com)
Human Research Ethics Committee approval has been granted by the Sydney Local Health District [X21-0392].
This research project will investigate the chronic pain that commonly occurs after spinal cord injury.
Using advanced brain imaging and other assessments, the project aims to:
(a) examine if 6-week treatment with CBD can reduce neuropathic pain
(b) to better understand the specific changes occurring in the brain after SCI that lead to the development of chronic neuropathic pain.
Chief Investigator: Professor Luke Henderson (Brain and Mind Centre, School of Medical Sciences, University of Sydney)
Trial Coordinator: Anastasia Suraev (Lambert Initiative, University of Sydney)
If you are interested in participating in this study, please call 0439 804 551 or email (firstname.lastname@example.org).
You can also register your interest via our online pre-screening survey: https://bit.ly/SCAN_study
Human Research Ethics Committee approval has been granted by the University of Sydney [2021/936]
We have a number of clinical trials that are yet to start recruiting. Check back soon for updates.
Many people with epilepsy continue to face barriers in accessing medicinal cannabis, suggesting that further refinements to the Australian treatment framework may be beneficial.
This survey will help us better understand the lived experience of individuals with epilepsy are currently using or have previously used, illicit and/or prescribed, medicinal cannabis to treat their epilepsy.
The results of this survey will provide us with invaluable information that we can use to better advocate for the needs of people with epilepsy when speaking to policymakers and health professionals about cannabinoid medicines.
You can take part in this research study if you are:
Trial Coordinator: Dr Anastasia Suraev (Lambert Initiative, University of Sydney)
Research Team: Douglas Skene (Master of Brain and Mind Sciences, University of Sydney), Professor Iain McGregor (Lambert Initiative, University of Sydney)
For more information, and to get involved, please click here.
This project is a collaboration between the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney and Epilepsy Action Australia.
Human Research Ethics Committee approval has been granted by the University of Sydney [2023/313].